Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
17.07
+0.08 (0.47%)
Dec 26, 2024, 4:00 PM EST - Market closed
Company Description
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
The company is based in Zug, Switzerland.
Oculis Holding AG
| Country | Switzerland |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Riad Sherif |
Contact Details
Address: Bahnhofstrasse 7 Zug, 6300 Switzerland | |
| Phone | 41 41 711 9325 |
| Website | oculis.com |
Stock Details
| Ticker Symbol | OCS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| CIK Code | 0001953530 |
| ISIN Number | CH1242303498 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Riad Sherif | Chief Executive Officer |
| Sylvia Cheung | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 6-K | Report of foreign issuer |
| Sep 6, 2024 | EFFECT | Notice of Effectiveness |
| Sep 6, 2024 | 424B3 | Prospectus |
| Aug 30, 2024 | UPLOAD | Filing |
| Aug 27, 2024 | F-3 | Filing |
| Aug 27, 2024 | 6-K | Report of foreign issuer |
| Jun 10, 2024 | 6-K | Report of foreign issuer |